User menu

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Bibliographic reference Van Bockstal, Mieke ; Lambein, Kathleen ; Denys, Hannelore ; Braems, Geert ; Nuyts, Ann ; et. al. Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.. In: Virchows Archiv : an international journal of pathology, Vol. 465, no.3, p. 275-289 (2014)
Permanent URL
  1. Allred D.Craig, Clark Gary M., Molina Rafael, Tandon Atul K., Schnitt Stuart J., Gilchrist Kennedy W., Osborne C.Kent, Tormey Douglass C., McGuire William L., Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer, 10.1016/0046-8177(92)90257-4
  2. Altintas Sevilay, Lambein Kathleen, Huizing Manon T., Braems Geert, Asjoe Fernando Tjin, Hellemans Hilde, Van Marck Eric, Weyler Joost, Praet Marleen, Van den Broecke Rudy, Vermorken Jan B., Tjalma Wiebren A., Prognostic Significance of Oncogenic Markers in Ductal Carcinoma In Situ of the Breast: A Clinicopathologic Study, 10.1111/j.1524-4741.2009.00686.x
  3. Barnes D.M., Smith P.J., Millis R.R., Bartkova J., Camplejohn R.S., Gullick W.J., Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?, 10.1016/s0959-8049(05)80117-0
  4. Bijker N., Donker M., Wesseling J., den Heeten G. J., Rutgers E. J. Th., Is DCIS Breast Cancer, and How Do I Treat it?, 10.1007/s11864-012-0217-1
  5. Burkhardt L., Grob T. J., Hermann I., Burandt E., Choschzick M., Jänicke F., Müller V., Bokemeyer C., Simon R., Sauter G., Wilczak W., Lebeau A., Gene amplification in ductal carcinoma in situ of the breast, 10.1007/s10549-009-0675-8
  6. Cheang Maggie C. U., Chia Stephen K., Voduc David, Gao Dongxia, Leung Samuel, Snider Jacqueline, Watson Mark, Davies Sherri, Bernard Philip S., Parker Joel S., Perou Charles M., Ellis Matthew J., Nielsen Torsten O., Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, 10.1093/jnci/djp082
  7. Clark S E, Warwick J, Carpenter R, Bowen R L, Duffy S W, Jones J L, Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease, 10.1038/sj.bjc.6606021
  8. Claus Elizabeth B., Chu Peiguo, Howe Christine L., Davison Tracey L., Stern David F., Carter Darryl, DiGiovanna Michael P., Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors, 10.1006/exmp.2001.2366
  9. Cuzick Jack, Sestak Ivana, Pinder Sarah E, Ellis Ian O, Forsyth Sharon, Bundred Nigel J, Forbes John F, Bishop Hugh, Fentiman Ian S, George William D, Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial, 10.1016/s1470-2045(10)70266-7
  10. Ferretti Gianluigi, Felici Alessandra, Papaldo Paola, Fabi Alessandra, Cognetti Francesco, HER2/neu role in breast cancer: from a prognostic foe to a predictive friend : , 10.1097/gco.0b013e328012980a
  11. Giordano Cinzia, Vizza Donatella, Panza Salvatore, Barone Ines, Bonofiglio Daniela, Lanzino Marilena, Sisci Diego, De Amicis Francesca, Fuqua Suzanne A.W., Catalano Stefania, Andò Sebastiano, Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells, 10.1016/j.molonc.2012.11.002
  12. Goldhirsch A., Winer E. P., Coates A. S., Gelber R. D., Piccart-Gebhart M., Thürlimann B., Senn H.-J., Albain Kathy S., André Fabrice, Bergh Jonas, Bonnefoi Hervé, Bretel-Morales Denisse, Burstein Harold, Cardoso Fatima, Castiglione-Gertsch Monica, Coates Alan S., Colleoni Marco, Costa Alberto, Curigliano Giuseppe, Davidson Nancy E., Di Leo Angelo, Ejlertsen Bent, Forbes John F., Gelber Richard D., Gnant Michael, Goldhirsch Aron, Goodwin Pamela, Goss Paul E., Harris Jay R., Hayes Daniel F., Hudis Clifford A., Ingle James N., Jassem Jacek, Jiang Zefei, Karlsson Per, Loibl Sibylle, Morrow Monica, Namer Moise, Kent Osborne C., Partridge Ann H., Penault-Llorca Frédérique, Perou Charles M., Piccart-Gebhart Martine J., Pritchard Kathleen I., Rutgers Emiel J.T., Sedlmayer Felix, Semiglazov Vladimir, Shao Zhi-Ming, Smith Ian, Thürlimann Beat, Toi Masakazu, Tutt Andrew, Untch Michael, Viale Giuseppe, Watanabe Toru, Wilcken Nicholas, Winer Eric P., Wood William C., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, 10.1093/annonc/mdt303
  13. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC, American Society of Clinical O, College of American P (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–e72. doi: 10.1043/1543-2165-134.7.e48
  14. Han K., Nofech-Mozes S., Narod S., Hanna W., Vesprini D., Saskin R., Taylor C., Kong I., Paszat L., Rakovitch E., Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence, 10.1016/j.clon.2011.09.008
  15. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481
  16. Holmes Phoebe, Lloyd Joshua, Chervoneva Inna, Pequinot Edward, Cornfield Dennis B., Schwartz Gordon F., Allen Kathleen G., Palazzo Juan P., Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone, 10.1002/cncr.25942
  17. Hoorntje Lidewij E., Schipper Marguerite E. I., Peeters Petra H. M., Bellot Frank, Storm Remmert K., Borel Rinkes Inne H. M., The Finding of Invasive Cancer After a Preoperative Diagnosis of Ductal Carcinoma-In-Situ: Causes of Ductal Carcinoma-In-Situ Underestimates With Stereotactic 14-Gauge Needle Biopsy, 10.1245/aso.2003.11.011
  18. Horimoto Yoshiya, Tokuda Emi, Arakawa Atsushi, Kosaka Taijiro, Saito Mitsue, Kasumi Fujio, Significance of HER2 Protein Examination in Ductal Carcinoma In Situ, 10.1016/j.jss.2009.07.030
  19. Jang Min Hye, Kim Eun Joo, Choi Yoomi, Lee Hee Eun, Kim Yu Jung, Kim Jee Hyun, Kang Eunyoung, Kim Sung-Won, Kim In Ah, Park So Yeon, FGFR1 is amplified during the progression of in situto invasive breast carcinoma, 10.1186/bcr3239
  20. Kepple Julie, Henry-Tillman Ronda S., Klimberg V. Suzanne, Layeeque Rakshanda, Siegel Eric, Westbrook Kent, Korourian Soheila, The receptor expression pattern in ductal carcinoma in situ predicts recurrence, 10.1016/j.amjsurg.2006.04.002
  21. Kerlikowske K., Molinaro A. M., Gauthier M. L., Berman H. K., Waldman F., Bennington J., Sanchez H., Jimenez C., Stewart K., Chew K., Ljung B. M., Tlsty T. D., Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis, 10.1093/jnci/djq101
  22. Knudsen Erik S., Pajak Thomas F., Qeenan Maria, McClendon A. Kathleen, Armon Benjamin D., Schwartz Gordon F., Witkiewicz Agnieszka K., Retinoblastoma and Phosphate and Tensin Homolog Tumor Suppressors: Impact on Ductal Carcinoma In Situ Progression, 10.1093/jnci/djs446
  23. Kulkarni Swati, Patil Deepa B, Diaz Leslie K, Wiley Elizabeth L, Morrow Monica, Khan Seema A, COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ, 10.1186/1471-2407-8-36
  24. Lambein K., Praet M., Forsyth R., Van den Broecke R., Braems G., Matthys B., Cocquyt V., Denys H., Pauwels P., Libbrecht L., Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations, 10.1136/jcp.2010.084863
  25. Lambein K, Van Bockstal M, Denys H, Libbrecht L (2014) 2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. J Clin Oncol. doi: 10.1200/JCO.2013.54.2530
  26. Lambein K., Van Bockstal M., Vandemaele L., Geenen S., Rottiers I., Nuyts A., Matthys B., Praet M., Denys H., Libbrecht L., Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer: Clinical and Pathobiological Relevance, 10.1309/ajcp4a7ktayhzsoe
  27. Latta E. K., Tjan S., Parkes R. K., O’Malley F. P., The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the Breast, 10.1097/
  28. Liao Ning, Zhang Guo-chun, Liu Yan-hui, Li Xue-rui, Yao Meng, Xu Fang-ping, Li Li, Wu Yi-long, HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component, 10.1016/j.prp.2010.08.005
  29. Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W (2008) Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol 2:7–18
  30. Noh Jae Myoung, Lee Jihae, Choi Doo Ho, Cho Eun Yoon, Huh Seung Jae, Park Won, Nam Seok Jin, Lee Jeong Eon, Kil Won-Ho, HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy, 10.1016/j.breast.2013.04.001
  31. Park K, Han S, Kim H J, Kim J, Shin E, HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry, 10.1111/j.1365-2559.2006.02403.x
  32. Perez Edith A., Reinholz Monica M., Hillman David W., Tenner Kathleen S., Schroeder Matthew J., Davidson Nancy E., Martino Silvana, Sledge George W., Harris Lyndsay N., Gralow Julie R., Dueck Amylou C., Ketterling Rhett P., Ingle James N., Lingle Wilma L., Kaufman Peter A., Visscher Daniel W., Jenkins Robert B., HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial, 10.1200/jco.2009.26.2154
  33. Pinder S E, Duggan C, Ellis I O, Cuzick J, Forbes J F, Bishop H, Fentiman I S, George W D, A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial, 10.1038/sj.bjc.6605718
  34. Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M (2012) Microinvasive carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) World Health Organization classification of tumours. WHO Press, Geneva, pp 95–97
  35. Punglia R. S., Schnitt S. J., Weeks J. C., Treatment of Ductal Carcinoma In Situ After Excision: Would a Prophylactic Paradigm Be More Appropriate?, 10.1093/jnci/djt256
  36. Qian Lu, Chen Liyong, Shi Ming, Yu Ming, Jin Baofeng, Hu Meiru, Xia Qing, Zhang Xueming, Shen Beifen, Guo Ning, A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells, 10.1016/j.bbrc.2006.04.153
  37. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L, HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ, 10.1038/bjc.2012.41
  38. Rauch Gaiane M., Kuerer Henry M., Scoggins Marion E., Fox Patricia S., Benveniste Ana P., Park Young Mi, Lari Sara A., Hobbs Brian P., Adrada Beatriz E., Krishnamurthy Savitri, Yang Wei T., Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status, 10.1007/s10549-013-2598-7
  39. Roses R. E., Paulson E. C., Sharma A., Schueller J. E., Nisenbaum H., Weinstein S., Fox K. R., Zhang P. J., Czerniecki B. J., HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer, 10.1158/1055-9965.epi-08-1101
  40. Sauter Guido, Lee James, Bartlett John M.S., Slamon Dennis J., Press Michael F., Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations, 10.1200/jco.2007.14.8197
  41. Poller D.N., Barth A., Slamon D.J., Silverstein M.J., Gierson E.D., Coburn W.J., Waisman J.R., Gamagami P., Lewinsky B.S., Prognostic classification of breast ductal carcinoma-in-situ, 10.1016/s0140-6736(95)90982-6
  42. Siziopikou Kalliopi P., Anderson Stewart J., Cobleigh Melody A., Julian Thomas B., Arthur Douglas W., Zheng Ping, Mamounas Eleftherios P., Pajon Eduardo R., Behrens Robert J., Eakle Janice F., Leasure Nick C., Atkins James N., Polikoff Jonathan A., Seay Thomas E., McCaskill-Stevens Worta J., Rabinovitch Rachel, Costantino Joseph P., Wolmark Norman, Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43, 10.1007/s10549-013-2755-z
  43. Tamimi Rulla M, Baer Heather J, Marotti Jonathan, Galan Mark, Galaburda Laurie, Fu Yineng, Deitz Anne C, Connolly James L, Schnitt Stuart J, Colditz Graham A, Collins Laura C, Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer, 10.1186/bcr2128
  44. Van Bockstal Mieke, Lambein Kathleen, Gevaert Olivier, De Wever Olivier, Praet Marleen, Cocquyt Veronique, Van den Broecke Rudy, Braems Geert, Denys Hannelore, Libbrecht Louis, Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinomain situof the breast, 10.1111/his.12188
  45. Wapnir I. L., Dignam J. J., Fisher B., Mamounas E. P., Anderson S. J., Julian T. B., Land S. R., Margolese R. G., Swain S. M., Costantino J. P., Wolmark N., Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS, 10.1093/jnci/djr027
  46. Wolff Antonio C., Hammond M. Elizabeth H., Hicks David G., Dowsett Mitch, McShane Lisa M., Allison Kimberly H., Allred Donald C., Bartlett John M.S., Bilous Michael, Fitzgibbons Patrick, Hanna Wedad, Jenkins Robert B., Mangu Pamela B., Paik Soonmyung, Perez Edith A., Press Michael F., Spears Patricia A., Vance Gail H., Viale Giuseppe, Hayes Daniel F., Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update, 10.1200/jco.2013.50.9984
  47. Wolff Antonio C., Hammond M. Elizabeth H., Schwartz Jared N., Hagerty Karen L., Allred D. Craig, Cote Richard J., Dowsett Mitchell, Fitzgibbons Patrick L., Hanna Wedad M., Langer Amy, McShane Lisa M., Paik Soonmyung, Pegram Mark D., Perez Edith A., Press Michael F., Rhodes Anthony, Sturgeon Catharine, Taube Sheila E., Tubbs Raymond, Vance Gail H., van de Vijver Marc, Wheeler Thomas M., Hayes Daniel F., American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer, 10.1200/jco.2006.09.2775
  48. Yang Ming, Moriya Takuya, Oguma Mitsue, De La Cruz Clarissa, Endoh Mareyuki, Ishida Takanori, Hirakawa Hisashi, Orita Yojiro, Ohuchi Noriaki, Sasano Hironobu, Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases, 10.1046/j.1440-1827.2003.01498.x